AbbVie Inc. $ABBV Stock Bought by Investment Partners LTD.

Key Points

• Investment Partners LTD. increased its AbbVie stake by 82.2% in the third quarter, bringing its holdings to 10,925 shares valued at approximately $2.86 million. Institutional investors and hedge funds collectively own 70.23% of AbbVie.
• AbbVie beat quarterly expectations with earnings of $3.82 per share versus the $3.73 consensus, while revenue rose 10.3% year over year to $17.40 billion. The company declared a quarterly dividend of $1.73, equivalent to an annualized yield of about 2.3%.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $279.86, although the stock was trading near its 52-week high at $294.80. Investors remain focused on valuation and reliance on growth from Skyrizi and Rinvoq as Humira revenue continues to decline.

Investment Partners LTD. increased its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 82.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,925 shares of the company's stock after acquiring an additional 4,928 shares during the quarter. Investment Partners LTD.'s holdings in AbbVie were worth $2,858,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Burk Holdings LLC acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $30,000. Marquette Asset Management LLC raised its position in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock valued at $35,000 after buying an additional 48 shares in the last quarter. IMG Wealth Management Inc. boosted its stake in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock valued at $40,000 after buying an additional 153 shares during the period. Principia Wealth Advisory LLC boosted its stake in shares of AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock valued at $40,000 after buying an additional 44 shares during the period. Finally, Tacita Capital Inc acquired a new stake in AbbVie during the second quarter worth approximately $42,000. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Trading Up 1.4%

Shares of NYSE ABBV opened at $294.80 on Friday. The company has a market cap of $520.85 billion, a price-to-earnings ratio of 50.74, a PEG ratio of 1.35 and a beta of 0.24. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $298.74. The stock has a 50-day moving average price of $269.35 and a two-hundred day moving average price of $237.23.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts' consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $1.86 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Thursday, October 15th. AbbVie's dividend payout ratio is presently 195.48%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ABBV. HSBC upped their target price on AbbVie from $300.00 to $315.00 and gave the company a "buy" rating in a research report on Thursday, September 10th. BNP Paribas Exane boosted their price target on AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a research note on Tuesday, August 11th. Weiss Ratings raised shares of AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. The Goldman Sachs Group increased their price objective on shares of AbbVie from $258.00 to $294.00 and gave the stock a "neutral" rating in a research note on Friday, October 23rd. Finally, Wells Fargo & Company raised their target price on shares of AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $279.86.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.